Buy Rating Affirmed: Strategic Partnerships and Clinical Milestones Propel Wave Life Sciences' Growth Potential

TipRanksApr 26 14:16

Wave Life Sciences: A Promising Buy Rating Based on Strategic GSK Collaboration and Innovative SiRNA Platform

TipRanksApr 26 14:11

Edgewise Gets EU Orphan Drug Status for Muscular Dystrophy Drug

Seeking AlphaApr 23 22:29

As Part Of Wave Life Sciences' Ongoing Collaboration With GSK, GSK Has Selected Its First Two Oligonucleotide Programs, GSK Will Provide An Initiation Payment Of $12M

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNA

BenzingaApr 23 22:22

Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in SiRNA and RNA Editing

GSK has selected the first two programs to advance following achievement of target validation, marking transition to next phase of research collaboration; programs utilize Wave's next generation GalNAc-siRNA format with

GlobeNewswireApr 23 20:30

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, although Amazon.com made losses for many years after l

Simply Wall StApr 9 18:50